Product Images Desvenlafaxine Succinate

This is a description of Desvenlafaxine, an extended-release tablet containing 100 mg of desvenlafaxine succinate. The recommended dosage can be found in the package insert. It is advised to store the tablets at a temperature range of 20° to 25°C (68° to 77°F), with excursions permitted between 15° to 30°C (59° to 86°F). The medication guide for patients is available at www.macleodspharma.com/usa. The tablets are dispensed in a pack of 30 tablets. The product is manufactured by Macleods Pharma USA, Inc., located in Princeton, NJ, for Macleods Pharmaceuticals Ltd in Baddi, Himachal Pradesh, India.*

This is the information for Desvenlafaxine Extended-Release Tablets. Each bottle contains 90 tablets, each tablet contains succinate equivalent to 100 mg desvenlafaxine. The usual dosage can be found in the package insert. The Pharmacist should dispense the accompanying Medication Guide to each patient. Store the tablets at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). The tablets are manufactured by Macleods Pharmaceuticals Ltd. in India and distributed by Macleods Pharma USA, Inc. in Princeton, NJ.*

This is the information for Desvenlafaxine Extended-Release Tablets by MACLEODY Pharma USA. Each tablet contains 152 mg of desvenlafaxine succinate equivalent to 100 mg of desvenlafaxine. The medication is dispensed with a Medication Guide available online. The tablets should be stored at 20° to 25°C (68° to 77°F) with excursions permitted to 15° to 30°C (59° to 86°F). The batch number is provided for tracking purposes. The manufacturer is Macleods Pharmaceuticals Ltd. in India with distribution in the USA.*

Desvenlafaxine Extended-Release Tablets 50mg packaged as R Only with 30 tablets per container. Each tablet contains 76 mg of desvenlafaxine succinate equivalent to 50 mg desvenlafaxine. It is recommended to dispense the accompanying Medication Guide to patients as per the pharmacist's instruction. For usual dosage, refer to the package insert. The product should be stored at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). Manufactured by Macleods Pharmaceuticals Ltd. for Macleods Pharma USA, Inc. in Princeton, NJ.*

This text provides information about Desvenlafaxine extended-release tablets, containing 50mg of desvenlafaxine succinate, equivalent to 76mg of desvenlafaxine. It directs the pharmacist to dispense the medication guide with each patient and mentions the usual dosage. The tablets are to be stored at 20°C to 25°C, with excursions permitted to 15°C to 30°C. The product is manufactured by Macleods Pharma USA, Inc. in Princeton, NJ.*

This text provides information about Desvenlafaxine Extended-Release Tablets in 50 mg strength from Macleods Pharma USA. The tablets are to be stored at 20° to 25°C and each tablet contains 76 mg of desvenlafaxine succinate, equivalent to 50 mg of desvenlafaxine. The batch number and manufacturing details are also included. Additionally, it mentions the pharmacist's instruction to dispense the accompanying Medication Guide to each patient. Further details and dosage instructions can be found on the provided website. The tablets are manufactured by Macleods Pharmaceuticals Ltd. in India.*

This data table illustrates the impact of intrinsic factors such as renal impairment, hepatic impairment, and population description on the pharmacokinetics of Desvenlafaxine. The geometric mean ratios with 90% confidence intervals are provided for different levels of renal impairment, hepatic impairment, and population subgroups based on gender and age. The table shows how these intrinsic factors can influence the maximum concentration (Cmax) and area under the curve (AUC) of Desvenlafaxine. Additionally, there is a note explaining ESRD as End-Stage Renal Disease for reference.*

This text provides information on the effect of other drugs, particularly CYP3A4 inhibitors like Ketoconazole, on the pharmacokinetics of Desvenlafaxine. It shows the geometric mean ratio (90% CI) for the change in AUC when Ketoconazole is used, which is 1.43 (1.38-1.49). The text also mentions a reference change for the evaluation.*

This text provides data on the estimated proportion of patients experiencing a relapse over time, specifically comparing those taking Desvenlafaxine 50mg to those on Placebo. The chart shows the relationship between the time to relapse (in days from randomization) and the likelihood of experiencing a relapse. The figures suggest that the group on Desvenlafaxine 50mg may have a lower relapse rate compared to the Placebo group.*

This text provides information about the relapse rate (%) over time for patients taking Desvenlafaxine versus Placebo. It includes a graph showing the estimated proportion of patients experiencing relapse over time (in days from randomization).*